Fluorine-18 Labeled Urea-Based Ligands Targeting Prostate-Specific Membrane Antigen (PSMA) with Increased Tumor and Decreased Renal Uptake.

PET PSMA biodistribution fluorine-18 lipophilicity oxime

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
13 May 2022
Historique:
received: 05 04 2022
revised: 07 05 2022
accepted: 11 05 2022
entrez: 28 5 2022
pubmed: 29 5 2022
medline: 29 5 2022
Statut: epublish

Résumé

High expression of prostate-specific membrane antigen (PSMA) in prostate cancers prompted the development of the PSMA-targeted PET-imaging agent [

Identifiants

pubmed: 35631423
pii: ph15050597
doi: 10.3390/ph15050597
pmc: PMC9144807
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : NIH HHS
ID : HHSN261200800001E
Pays : United States

Références

Clin Cancer Res. 2008 May 15;14(10):3036-43
pubmed: 18483369
J Nucl Med. 2016 Oct;57(Suppl 3):43S-48S
pubmed: 27694171
Neoplasia. 2020 Nov;22(11):566-575
pubmed: 32980775
J Nucl Med. 2018 Jul;59(7):1076-1080
pubmed: 29269569
Cancer Imaging. 2019 May 15;19(1):23
pubmed: 31092293
Mod Pathol. 2015 Jan;28(1):138-45
pubmed: 24925052
J Nucl Med. 2021 May 10;62(5):596-604
pubmed: 33712536
Mol Pharm. 2009 May-Jun;6(3):790-800
pubmed: 19361232
Cancers (Basel). 2021 Jul 23;13(15):
pubmed: 34359614
Mol Imaging Biol. 2015 Aug;17(4):575-84
pubmed: 26013479
J Nucl Med. 2019 Jul;60(7):955-962
pubmed: 30683770
Mol Imaging Biol. 2019 Jun;21(3):558-566
pubmed: 30105521
Mol Imaging Biol. 2015 Aug;17(4):565-74
pubmed: 25896814
Dalton Trans. 2019 Nov 14;48(42):15856-15868
pubmed: 31617517
Semin Nucl Med. 2019 Jul;49(4):302-312
pubmed: 31227053
Ann Nucl Med. 2013 Jan;27(1):46-57
pubmed: 23086544
World J Oncol. 2019 Apr;10(2):63-89
pubmed: 31068988
Radiographics. 2018 Jan-Feb;38(1):200-217
pubmed: 29320333
J Nucl Med. 2017 Mar;58(3):425-431
pubmed: 27789722
Nat Rev Urol. 2009 Jun;6(6):317-23
pubmed: 19434102
J Labelled Comp Radiopharm. 2018 Jun 30;61(8):599-605
pubmed: 29575176
Bioconjug Chem. 2012 Apr 18;23(4):688-97
pubmed: 22369515
Clin Adv Hematol Oncol. 2019 Aug;17(8):455-463
pubmed: 31449514
Mol Imaging Biol. 2015 Dec;17(6):777-85
pubmed: 25869080
Pharmaceuticals (Basel). 2021 Jul 23;14(8):
pubmed: 34451810
J Nucl Med. 2017 Oct;58(10):1545-1552
pubmed: 28687599
Asian Pac J Cancer Prev. 2018 Apr 27;19(4):1041-1046
pubmed: 29699054
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):960-968
pubmed: 28280856
Theranostics. 2020 Jan 1;10(1):1-16
pubmed: 31903102
Nat Rev Urol. 2016 Apr;13(4):226-35
pubmed: 26902337
Nat Rev Drug Discov. 2022 May;21(5):327
pubmed: 35396355
Prostate Cancer Prostatic Dis. 2022 Mar;25(1):11-26
pubmed: 34050265
Mol Imaging Biol. 2021 Oct;23(5):745-755
pubmed: 33891265
J Nucl Med. 2019 Jun;60(6):817-823
pubmed: 30389823
Bioconjug Chem. 2011 Aug 17;22(8):1700-5
pubmed: 21740058
J Nucl Med. 2017 Jul;58(7):1081-1087
pubmed: 28209912
Histopathology. 2007 Mar;50(4):472-83
pubmed: 17448023
J Med Chem. 2016 Jun 23;59(12):5684-94
pubmed: 27228467
Am J Nucl Med Mol Imaging. 2018 Aug 20;8(4):247-267
pubmed: 30245917
J Nucl Med. 2019 Mar;60(3):362-368
pubmed: 30042163
Eur Urol. 2016 Dec;70(6):926-937
pubmed: 27363387
Curr Med Chem. 2012;19(6):856-70
pubmed: 22214450
Eur Urol. 2019 Jun;75(6):920-926
pubmed: 30473431
Clin Cancer Res. 2011 Dec 15;17(24):7645-53
pubmed: 22042970
J Med Chem. 2008 Dec 25;51(24):7933-43
pubmed: 19053825
Bioconjug Chem. 2003 Nov-Dec;14(6):1067-76
pubmed: 14624619
J Labelled Comp Radiopharm. 2017 Mar;60(3):168-175
pubmed: 27990672
Mol Imaging Biol. 2017 Dec;19(6):923-932
pubmed: 28639122
Front Oncol. 2018 Dec 20;8:623
pubmed: 30619757
J Nucl Med. 2017 Jun;58(6):947-952
pubmed: 27908968
Mol Imaging Biol. 2016 Jun;18(3):411-9
pubmed: 27080322
Cancer Res. 2009 Sep 1;69(17):6932-40
pubmed: 19706750
Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):486-95
pubmed: 23179945
Cancer Biother Radiopharm. 2020 May;35(4):284-291
pubmed: 32074455
Mol Diagn Ther. 2021 Sep;25(5):647-656
pubmed: 34292532
Diagnostics (Basel). 2021 Mar 19;11(3):
pubmed: 33808825

Auteurs

Falguni Basuli (F)

Chemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Tim E Phelps (TE)

Molecular Imaging Branch, National Cancer Institute, Bethesda, MD 20892, USA.

Xiang Zhang (X)

Chemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Carolyn C Woodroofe (CC)

Chemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Jyoti Roy (J)

Molecular Imaging Branch, National Cancer Institute, Bethesda, MD 20892, USA.

Peter L Choyke (PL)

Molecular Imaging Branch, National Cancer Institute, Bethesda, MD 20892, USA.

Rolf E Swenson (RE)

Chemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Elaine M Jagoda (EM)

Molecular Imaging Branch, National Cancer Institute, Bethesda, MD 20892, USA.

Classifications MeSH